Preferred Label : Nilotinib Tartrate;
NCIt definition : The tartrate salt form of nilotinib, an orally bioavailable aminopyrimidine-derivative
Bcr-Abl tyrosine kinase inhibitor, with antineoplastic activity. Designed to overcome
imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration,
nilotinib binds to and stabilizes the inactive conformation of the kinase domain of
the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the
constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated
proliferation of Philadelphia chromosome-positive (Ph ) chronic myeloid leukemia (CML)
cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth
factor receptor (PDGF-R; PDGFR), mast/stem cell growth factor receptor Kit (c-Kit),
and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and
discoidin domain-containing receptor 1 (DDR1).;
UNII : NGN88DE7TX;
CAS number : 1353151-37-7;
Origin ID : C213411;
chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_free_acid_or_base_form
